Helio Health, Inc.

Helio Health, Inc. is a tax-exempt nonprofit organization headquartered in Syracuse, New York, that delivers substance use disorder treatment, mental health counseling, crisis intervention, medication-assisted treatment, and supportive housing services to the federal government as a prime recipient (87% of recent awards) and grant sub-recipient. The organization competes on full-and-open federal grants and contracts with no set-aside designations.

Helio Health's federal portfolio splits between two distinct capability streams. The first is community-based behavioral health and housing services under the Department of Housing and Urban Development's Continuum of Care Program (CFDA 14.267), where Helio Health acts as prime recipient for recurring project grants supporting permanent supportive housing, rapid rehousing, transitional housing, supportive services, and homeless management information systems across Central Upstate New York. The second is federal inmate and home-confinement treatment services delivered under a single-award Indefinite Delivery Contract with the Department of Justice Bureau of Prisons (awarded March 1, 2025, with a ceiling of $2.1 million and a base period plus four one-year option periods extending through February 28, 2030). Representative delivery orders under the Bureau of Prisons IDIQ include a $34,400 order (March 1, 2025, through September 30, 2025) and a $218,887 order (March 1, 2026, through September 30, 2026), both for substance use and mental health treatment services in Syracuse, New York, firm fixed-price. The organization's place of performance is Syracuse, NY 13203, with service delivery requirements within a 5-mile radius of Syracuse City Hall and a half-mile of public transportation.

Customer concentration sits entirely with HUD and Department of Justice. HUD's Continuum of Care Program funds 155 awards across Helio Health's recent portfolio, representing the dominant share by count; the Department of Justice Bureau of Prisons Central Office anchors the dollar concentration with 38 awards worth $13.9 million in combined potential value. The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Mental Health Services and the Center for Substance Abuse Treatment together account for 24 awards, funding certified community behavioral health clinic (CCBHC) expansion and adult treatment drug court expansion projects. Helio Health also holds federal emergency management grants for COVID-related protective measures (now closed).

Helio Health's subcontract footprint focuses on New York State agencies rather than federal primes. The organization acts as sub-recipient on grant awards from the Research Foundation for Mental Hygiene (NYS OASAS SOR programs), the New York State Office of Mental Health (jail diversion, PATH, and workforce retention), and the New York State Division of Homeland Security and Emergency Services (pandemic emergency protective measures).

The organization's SAMHSA-funded grant work includes a Certified Community Behavioral Health Clinic Improvement Project ($1.2 million obligated, September 30, 2023, through September 29, 2027) focused on expanding 24/7 mobile crisis response and behavioral health services for children, youth, and families across five Central New York counties (Onondaga, Cayuga, Cortland, Madison, and Oswego), and a second CCBHC Pilot Demonstration Initiative grant (awarded September 30, 2022, through September 29, 2026) establishing a new clinic site at Insights of Helio Health in Utica to serve six Mohawk Valley counties (Fulton, Herkimer, Montgomery, Oneida, Otsego, and Schoharie). Helio Health also received a Substance Abuse and Mental Health Services Administration grant for the Oneida County Adult Treatment Drug Court Expansion Project (September 30, 2022, through September 29, 2027) to expand forensic case management, harm reduction training, and treatment support for justice-involved adults with substance use disorders.

Activity has held steady at roughly 20 awards per year across 2022 through 2025, with 14 awards in 2026 to date. Twelve awards (combined potential value $161 thousand) reach ultimate completion within the next twenty-four months, presenting moderate recompete exposure. The organization's recent obligated funding substantially exceeds its combined potential value (701% ratio), indicating that prior-year grants and contracts remain in active performance across multiple overlapping fiscal-year cycles.